| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-327 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-327
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2015-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2021-02-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-106456557-B |
| titleOfInvention |
Therapeutic agents used in the treatment of infections |
| abstract |
A nano- or micro-scale therapeutic agent for use in the treatment of infection in humans or animals is provided. The therapeutic agent includes a micro- and/or nano-particle carrier loaded alone or with at least one inert precursor chemical. The carrier encapsulates the one or more precursor chemicals, which upon release from the carrier can be activated in situ by the physiological environment at the site of infection to form antimicrobial agents. Preferably, the precursor chemical species upon release forms an oxidizing microbicide which is hydrogen peroxide. Preferably, the precursor chemistry further comprises an acetyl donor, which upon release reacts with hydrogen peroxide produced by the peroxygen donor to form a mixture of peracetic acid and hydrogen peroxide. The carrier is preferably in the form of micro- and/or nano-particles manufactured using a thermally induced phase separation (TIPS) process, for example, the carrier may comprise a biodegradable polymer such as poly(lactic-co-glycolic acid) (PLGA). |
| priorityDate |
2014-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |